Status:
COMPLETED
M Charts Versus Amsler Test in Evaluating Metamorphopsia in nAMD
Lead Sponsor:
Ospedale Santa Croce-Carle Cuneo
Conditions:
Macular Degeneration, Wet
Metamorphopsia
Eligibility:
All Genders
50+ years
Brief Summary
Age-related macular degeneration (AMD) is a complex eye disorder and the most common macular disease affecting millions of aged people in the developed countries, with an estimation that the number of...
Detailed Description
Introduction Age-related macular degeneration (AMD) is a complex eye disorder and the most common macular disease affecting millions of aged people in developed countries, with an estimation that the...
Eligibility Criteria
Inclusion
- Diagnosis of neovascular age-related macular degeneration with active CNV on fluorangiographic examination
- Visual acuity (VA) equal to or greater than 1.0 logMAR
- Written informed consent
- Age over 50.
Exclusion
- Prior intravitreal injection or intraocular surgery
- Major ocular diseases such as amblyopia, glaucoma, or strabismus, and refracting errors greater than 4D.
Key Trial Info
Start Date :
May 9 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 30 2023
Estimated Enrollment :
57 Patients enrolled
Trial Details
Trial ID
NCT05324150
Start Date
May 9 2022
End Date
September 30 2023
Last Update
November 2 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ospedale Santa Croce
Cuneo, Piedmont, Italy, 12100